Business News • PR NewsWire • NewLink Genetics' HyperAcute® Immunotherapy Phase 2 Study Shows Promise in Disease Free and Overall Survival for Resectable Pancreatic Cancer

NewLink Genetics' HyperAcute® Immunotherapy Phase 2 Study Shows Promise in Disease Free and Overall Survival for Resectable Pancreatic Cancer

NewLink Genetics' HyperAcute® Immunotherapy Phase 2 Study Shows Promise in Disease Free and Overall Survival for Resectable Pancreatic Cancer

CHICAGO, June 6 /PRNewswire/ -- NewLink Genetics Corporation today announced positive Phase 2 clinical trial data of its HyperAcute®-Pancreas cancer immunotherapy combined with standard adjuvant chemotherapy in patients with surgically resectable pancreatic cancer. The study results suggest a p

View More : http://www.prnewswire.com/news-releases/newlink-genetics-hyperacute-immunotherapy-phase-2-study-shows-promise-in-disease...

Releted News by prnewswire

U.S. Census Bureau Daily Feature for June 6

Queen Meg, Registered Nurses, and Everyday Californians Greet Meg Whitman, Pete Wilson in Fresno, Sacramento areas Sunday

Academy Award Winner Sandra Bullock Makes Surprise Appearance at Spike TV's 'Guy's Choice'

NewLink Genetics' HyperAcute® Immunotherapy Phase 2 Study Shows Promise in Disease Free and Overall Survival for Resectable Pancreatic Cancer

Data From Clinical Studies of bioTheranostics' CancerTYPE ID® and Breast Cancer Index® Molecular Oncology Tests Presented at ASCO 2010 Annual Meeting